<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660881</url>
  </required_header>
  <id_info>
    <org_study_id>SL0008</org_study_id>
    <secondary_id>EudraCT Number: 2007-002589-37</secondary_id>
    <nct_id>NCT00660881</nct_id>
  </id_info>
  <brief_title>Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease</brief_title>
  <official_title>A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety of epratuzumab in patients with
      SLE.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continue to assess safety of epratuzumab by assessing adverse events (including infusion reactions), vital signs and clinical safety laboratory assessments (Timeframe: All visits)</measure>
    <time_frame>12 Week treatment cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The combined response index analysis evaluating BILAG, SLEDAI, and a physician's global assessment and treatment failure status</measure>
    <time_frame>Every 4 weeks through week 48, then every 12 weeks through completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combined response index including an additional criteria involving the SF-36 response</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BILAG score assessment</measure>
    <time_frame>Every 4 weeks through week 48, then every 12 weeks through completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLEDAI scores assessment</measure>
    <time_frame>Every 4 weeks through week 48, then every 12 weeks through completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and physician VAS</measure>
    <time_frame>Every 4 weeks through week 48, then every 12 weeks through completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving SF-36 stabilization or improvement as compared to baseline</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 PCS, MCS</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D results</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients meeting treatment failure</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily steroid dose</measure>
    <time_frame>Every 4 weeks for the first 48 weeks and then every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to flare for patients who entered the study without flare as defined by the BILAG</measure>
    <time_frame>over the entire course of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLEDAI responder</measure>
    <time_frame>Every 4 weeks for the first 48 weeks and then every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained response for patients entering SL0008 with flare as defined by the BILAG.</measure>
    <time_frame>over the entire course of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by human anti-human antibodies</measure>
    <time_frame>at each dosing visit and 4 weeks post first dose of each treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in baseline in levels of circulating B and T cells</measure>
    <time_frame>The first dosing visit of each treatment cycle and at 4 weeks post first dose of each treatment cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>EMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.</description>
    <arm_group_label>EMAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SL0007 patients who completed through week 12 of the study or who early terminated at
             week 8 or later due to treatment failure

          -  Patients must have maintained eligibility requirements throughout their participation
             in SL0007

          -  Written informed consent signed prior to initiation of any study-specific assessments
             at visit 1

        Exclusion Criteria:

          -  Patients may not receive any live vaccination within 2 weeks prior to visit 1 or
             during the course of the study

          -  Active severe SLE disease activity which involves the CNS system (defined by BILAG
             neurologic A level activity) including transverse myelitis, psychosis and seizures

          -  Active severe SLE disease activity which involves the Renal system (defined by BILAG
             renal level A activity or Grade III or higher WHO nephritis) or serum creatinine
             &gt;2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks
             or proteinuria &gt;3.5gm/day

          -  Patients with a history of anti-phospholipid antibody syndrome AND Use of oral
             anticoagulants or anti-platelet treatment

          -  Patients with a history of chronic infection, recent significant infection, or any
             current sign of symptom that may indicate an infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madurai</city>
        <state>Tamilnadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manipal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <disposition_first_submitted>July 3, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 12, 2012</disposition_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>B-Cell immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

